Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Thrombosis
Interventions: Heparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Rochester, Minnesota • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Coronary Artery Disease, Heart Disease, Coronary Arteriosclerosis, Cardiovascular Disease, Myocardial Ischemia
Interventions: Not listed
Lead sponsor: Hartford Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 41
States / cities: Tucson, Arizona • Anaheim, California • Escondido, California + 35 more

Conditions: Cardiovascular Risk Factor
Interventions: Plant Sterol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stroke, Atherosclerosis
Interventions: High Risk - intensive coaching, High Risk - standard care, Low Risk - control; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Madison, Wisconsin • Oneida, Wisconsin

Conditions: Atrial Fibrillation, Risk Factors, Risk Reduction Behavior
Interventions: AliveCor mobile ECG cardiac monitor, AF Program, Standard of care; Other · Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Ischemic Stroke
Interventions: Balovaptan, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions: Home Monitoring Guided OAC, Physician-Directed OAC; Drug
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 73
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more

Conditions: Cardiovascular Risk Factor
Interventions: Ketone drink, Placebo drink; Dietary Supplement
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions: lecture; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kawasaki Disease
Interventions: Defibrotide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 0 Years to 11 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: New York, New York • Valhalla, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo; Drug · Dietary Supplement
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Long Beach, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Type 2 Diabetes, High Blood Pressure
Interventions: Polypill, Combined prescription of the individual medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obstructive Sleep Apnea Syndrome, Polycystic Ovary Syndrome, Sleep Apnea
Interventions: Nasal Continuous positive airway pressure (CPAP); Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified, Cigarette Smoking, Tobacco Use, Nicotine Dependence, Nicotine Withdrawal, Cardiovascular Risk Factor
Interventions: Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Brain Cancer, Thyroid Cancer, Circulatory Disease, Breast Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Cardiovascular Risk Factor, Physical Activity, Chronic Kidney Diseases
Interventions: FitBit; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions: JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions: nfant feeding solution; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Symptomatic Severe Aortic Stenosis
Interventions: TAVR Implantation with SAPIEN XT, SAVR Implantation; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 2,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 55
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 46 more

Conditions: Sudden Cardiac Death, Arrhythmias, Congestive Heart Failure, Cardiomyopathy
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 1,807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: Impaired Glucose Tolerance, Prediabetic State
Interventions: Aspirin, Alpha lipoic acid, Olmesartan, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions: Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: HIV, Acquired Immunodeficiency Syndrome, Cardiovascular Diseases
Interventions: Exercise Program, Control Group; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Weeks to 25 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?

Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients

Stroke Prevention in the Wisconsin Native American Population

Secondary Prevention of Atrial Fibrilation

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

Short Term Ketone Supplementation and Cardiometabolic Health

African American Community Health Project on Cardiovascular Disease

Defibrotide in Children With High Risk Kawasaki Disease

Thiazolidinedione Intervention With Vitamin D Evaluation

Polypill for Prevention of Cardiomyopathy

Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

THC Crossover Study

Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists

Activity Trackers for Improving BP

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk

Genetic Risk Assessment of Defibrillator Events

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV